Frontiers in Viral Hepatitis

by Schinazi; Sommadossi; Rice

• ISBN13: 9780444509864
• ISBN10: 0444509860
• Edition: 1st
• Format: Hardcover
• Copyright: 2003-12-12
• Publisher: Elsevier Science
• More Book Details
• Purchase Benefits

Summary

Frontiers in Viral Hepatitis provides a compilation of the research from over 40 key opinion leaders in the field of Hepatitis. The book focuses on the latest advances in the search for new, more effective therapeutic options and related topics in viral hepatitis. These include regulatory issues, epidemiology, and emerging viruses; immunology and vaccines; viral hepatitis B and C infections in children; genetics pathology and viral diagnosis; cell systems and animal models; novel therapeutics for hepatitis B and C; resistance and therapeutic strategies in humans; and prevention and treatment options for hepatocellular carcinoma.The breadth of information published in this volume provides insight into current prevention and treatment options. Recent advances in our understanding of the molecular biology, immunology and pathogenesis of hepatitis viruses have accelerated at a remarkable rate, offering a more comprehensive perspective on hepatitis.

Table of Contents

Preface	p. xi
Acknowledgments	p. xiv
Biographies	p. xv
Contributors	p. xix
Regulatory Issues, Epidemiology, and Emerging Viruses	p. 1
Current issues in the regulation and approval of antiviral drugs for hepatitis	p. 3
Molecular and serum epidemiology of HBV and HCV infection and the impact of antiviral agents in China	p. 15
New viruses and their relationship to hepatitis	p. 35
Immunology and Vaccines	p. 47
Virus-specific CD8+ cell immune responses in acute and chronic hepatitis B virus infection	p. 49
Cell-mediated immunity and the outcome of HCV infection in chimpanzees	p. 59
Adoptive immune transfer as a therapeutic approach for persistent hepatitis B virus infection	p. 71
Perspectives in HCV vaccine development	p. 77
Viral Hepatitis B and C Infections in Children	p. 87
Maternal/fetal/pediatric HBV and HCV infections	p. 89
Effects of interferon treatment in children with post-transfusional chronic hepatitis B	p. 97
Genetics, Pathology and Viral Diagnosis	p. 107
Effects of genotypic variations on hepatitis C virus nonstructural protein 5B structure and activity	p. 109
Compartmentalization of hepatitis C viral quasispecies	p. 123
In situ localization of PCR-amplified hepatitis C virus RNA on human erythrocytes	p. 131
Nucleic acid-based antiviral approaches to HBV	p. 139
In vitro phenotype of HBV variants in patients with fulminant hepatitis B	p. 157
Evaluation of three commercially available HBV viral load assays: dynamic range, precision, and clinical utility	p. 165
Cell Systems and Animal Models	p. 173
Cell lines that allow regulated expression of HCV proteins: principles and applications	p. 175
Novel hepatitis C virus-positive cell line derived from a chimpanzee with chronic HCV infection	p. 187
A transgenic mouse lineage useful for testing antivirals targeting hepatitis B virus	p. 197
Evaluation of therapies for hepatitis B virus in the HBV transgenic SCID mouse model	p. 211
Drug Discovery and Development: Novel Therapeutics for Hepatitis B and C	p. 223
Novel approaches in the management of chronic HBV infection	p. 225
Antiviral [beta]-L-nucleosides specific for hepatitis B virus infection	p. 245
Toxicological study of the anti-HBV agent [beta]-L-thymidine	p. 263
Pharmacokinetics of [beta]-L-thymidine and [beta]-L-2'-deoxycytidine in woodchucks and monkeys	p. 271
Clevudine: A novel 1-[beta]-L nucleoside analogue in clinical development for the treatment of HBV infection	p. 281
Glucosidase/protein folding inhibitors as possible mutation-proof, anti-hepatitis B & C agents	p. 301
Nuclease resistant ribozymes directed against hepatitis C virus RNA plus and minus strand inhibit viral replication of a HCV/poliovirus chimera	p. 315
Mechanism of laser therapy of viral hepatitis	p. 325
Drug Discovery and Development: Resistance and Therapeutic Strategies in Humans	p. 333
Nomenclature for antiviral resistant human hepatitis B virus mutations in the polymerase region	p. 335
Complex genotypic changes during failure of HBV nucleoside analogue therapy	p. 353
Lamivudine for chronic hepatitis B: Efficacy, safety, resistance, and current treatment issues	p. 365
Clinical experience and follow-up with lamivudine in the Asian population	p. 383
Impaired response to 5 mU/day interferon treatment in African-Americans with chronic hepatitis C	p. 391
Novel combined approaches to hepatitis C therapies	p. 399
Consensus + pegylated interferon	p. 413
Impact of interferon alpha-2b and of combination with ribavirin on progression of liver fibrosis in patients with chronic hepatitis C	p. 425
Decorin expression in chronic hepatitis C; effect of interferon alpha treatment	p. 441
Preclinical and clinical development of the anti-HIV, anti-HBV oxathiolane nucleoside analog emtricitabine	p. 451
CD81 receptor expression in human cells: Implications for HCV therapeutics	p. 485
Prevention and Treatment Options for Hepatocellular Carcinoma	p. 493
Resolution of hepatic fibrosis as a consequence of interferon therapy for hepatitis C	p. 495
Symptomatic therapies for prevention of hepatocellular carcinoma developing in chronic hepatitis C	p. 515
Mutations of the core gene sequence of HCV from patients with hepatocellular carcinoma in China	p. 531
Characterization of hepatitis B virus X variants that are integrated and expressed in human hepatocellular carcinomas	p. 547
Subject index	p. 557
Author index	p. 567
Table of Contents provided by Rittenhouse. All Rights Reserved.